Synermore Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 90

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

Synermore General Information

Description

Developer and researcher of biotechnology services intended to serve tumor diseases. The company's services primary researches to bring products from research stage through IND-enabling nonclinical and CMC activities to clinical stage of development, enabling clients to launch their products with certification.

Contact Information

Website
www.synermore.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 5, Sangtiandao Bio-Industry Park
  • Number 218 Sangtian Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Building 5, Sangtiandao Bio-Industry Park
  • Number 218 Sangtian Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215000
  • China
+86 0512

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synermore Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 26-Apr-2024 Completed Clinical Trials - Phase 1
3. Early Stage VC 01-Dec-2016 Completed Clinical Trials - Phase 1
2. Early Stage VC 11-Feb-2015 $8.25M $28.8M Completed Generating Revenue
1. Early Stage VC $20.6M $20.6M Completed Generating Revenue
To view Synermore’s complete valuation and funding history, request access »

Synermore Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • Pending

  • Expiring in next 12 mo

Synermore Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2804826-T3 Anti-egfr antibody and uses of it Active 16-Sep-2014
EP-3110447-A4 Anti-egfr antibody and uses of same Active 16-Sep-2014
EP-3110447-B1 Anti-egfr antibody and uses of same Active 16-Sep-2014
EP-3110447-A1 Anti-egfr antibody and uses of same Active 16-Sep-2014 C07K16/2863

Synermore Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synermore Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Sinovac Corporation Minority
CDIB Capital Group Venture Capital Minority
Morningside Group Venture Capital Minority
To view Synermore’s complete investors history, request access »

Ready to get started?

Request a free trial

Synermore Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Long Rui Pharma Shenzhen, China 2003

Synermore FAQs

  • When was Synermore founded?

    Synermore was founded in 2016.

  • Where is Synermore headquartered?

    Synermore is headquartered in Suzhou, China.

  • What is the size of Synermore?

    Synermore has 90 total employees.

  • What industry is Synermore in?

    Synermore’s primary industry is Biotechnology.

  • Is Synermore a private or public company?

    Synermore is a Private company.

  • What is Synermore’s current revenue?

    The current revenue for Synermore is .

  • How much funding has Synermore raised over time?

    Synermore has raised $56.4M.

  • Who are Synermore’s investors?

    Sinovac, CDIB Capital Group, and Morningside Group have invested in Synermore.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »